Consensus Abbott Laboratories Wiener Boerse
Stocks
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.98 EUR | +1.31% |
|
+6.89% | -16.86% |
| 08:31pm | Abbott Laboratories Seen on Track for H2 Growth Acceleration, RBC Says | MT |
| 05:26pm | JPMorgan Adjusts Price Target on Abbott Laboratories to $120 From $110, Maintains Overweight Rating | MT |
Evolution of the Average Target: Abbott Laboratories
Evolution of the Target Price: Abbott Laboratories
Changes in Analyst Recommendations: Abbott Laboratories
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | ||
| +17.09% | |||||
| +14.78% | |||||
| +12.15% | |||||
| +23.87% | |||||
| +9.96% | |||||
| +5.4% | |||||
| +23.91% | |||||
| +16.16% | |||||
| +34.19% | |||||
| Average | +17.50% | |||||
| Weighted average by Cap. | +16.62% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Wells Fargo Securities | |
| Evercore ISI | |
| Baird | |
| BofA Securities | |
| Goldman Sachs | |
| Daiwa Securities | |
| Leerink Partners | |
| Argus | |
| UBS | |
| Oppenheimer | |
| TD Cowen | |
| Citigroup | |
| Benchmark Company | |
| Stifel Nicolaus | |
| Jefferies & Co. | |
| Piper Sandler | |
| JPMorgan Chase | |
| Mizuho Securities | |
| RBC Capital Markets | |
| Raymond James | |
| Bernstein | |
| Barclays | |
| BTIG | |
| Rothschild & Co Redburn | |
| Morgan Stanley | |
| Redburn Atlantic | |
| Nephron Research | |
| Morningstar | |
| Wolfe Research | |
| Atlantic Equities | |
| SVB Leerink | |
| Redburn | |
| Cowen | |
| Credit Suisse | |
| J.P. Morgan Chase |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ABT Stock
- ABT Stock
- Consensus Abbott Laboratories
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
